Vimarsana
Biggest News Aggregation in the World

Page 3 - Parallel Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Parallel Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Parallel Session Today - Breaking & Trending Today

SCO Youth Technology and Innovation Forum concludes in Shenzhen - Vimarsana News

SCO Youth Technology and Innovation Forum concludes in Shenzhen

/PRNewswire/ -- A news release from GLOBAL TIMES ONLINE: The three-day Shanghai Cooperation Organization (SCO)Youth Technology and Innovation Forum dropped its...

GLOBAL TIMES ONLINE: SCO Youth Technology and Innovation Forum concludes in Shenzhen - Vimarsana News

GLOBAL TIMES ONLINE: SCO Youth Technology and Innovation Forum concludes in Shenzhen

BEIJING, June 6, 2022 /PRNewswire/ -- A news release from GLOBAL TIMES ONLINE: The three-day Shanghai Cooperation Organization (SCO)Youth Technology and Innovation Forum dropped its curtain

Beijing Jiandanshiji Culture Media Co., Ltd.: SCO Youth Technology and Innovation Forum concludes in Shenzhen - Vimarsana News

Beijing Jiandanshiji Culture Media Co., Ltd.: SCO Youth Technology and Innovation Forum concludes in Shenzhen

SHENZHEN, China, June 4, 2022 /PRNewswire/ -- A report from Jiandanshiji: The three-day Shanghai Cooperation Organization (SCO)Youth Technology and Innovation Forum dropped its curtain

Aeterna Zentaris Abstract Accepted for Presentation at 13th - Vimarsana News

Aeterna Zentaris Abstract Accepted for Presentation at 13th

– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan...

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress - Vimarsana News

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it